TL;DR: UnitedHealthcare modified its experimental and investigational procedures coverage policy, effective September 26, 2025. Here's what billing teams need to know about IDE study coverage, Category A vs. Category B device payment responsibility, and clinical trial reimbursement under Medicare Advantage plans.
| Field | Detail |
|---|---|
| Payer | UnitedHealthcare |
| Policy | Experimental Procedures and Items, Investigational Devices, and Clinical Trials |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | 2025-09-26 |
| Impact Level | High |
| Specialties Affected | All specialties billing Medicare Advantage; oncology, cardiology, device-heavy surgical specialties, clinical trial sites |
| Key Action | Audit all claims involving IDE studies and clinical trials against CMS approval status before billing UnitedHealthcare Medicare Advantage plans |
UnitedHealthcare Experimental and Investigational Coverage Policy: What Changed in 2025
UnitedHealthcare's coverage policy for experimental procedures, investigational devices, and clinical trials draws a hard line: anything the plan considers experimental or investigational is not Reasonable and Necessary. That's the policy's foundation, and it hasn't moved.
What this update clarifies — and where your billing team needs to pay close attention — is the payment responsibility framework for IDE studies under Medicare Advantage. The rules differ significantly based on whether a device is Category A or Category B. Getting this wrong sends claims to the wrong payer, triggers claim denial, and creates collection problems that are hard to unwind.
This policy directly references CMS's centralized IDE review process, effective January 1, 2015 under 42 CFR § 405 Subpart B. If your team hasn't aligned your experimental and investigational billing guidelines with that framework, this update is your signal to do it now.
UnitedHealthcare IDE Study and Clinical Trial Coverage Criteria and Medical Necessity Requirements 2025
The core medical necessity standard here is straightforward: experimental and investigational procedures, items, and medications are not covered. UnitedHealthcare will not reimburse for them as standard benefits.
But Investigational Device Exemption (IDE) studies operate under a separate set of rules — and those rules hinge entirely on CMS approval status and device category.
What Makes an IDE Study Coverable
For an IDE study to generate any reimbursable claims under a UnitedHealthcare Medicare Advantage plan, the study must be CMS-approved. Local MAC approval is no longer sufficient. CMS centralized IDE study review in 2015. If a study only has MAC-level approval from before that change and was never re-approved under the centralized process, your claims are at risk.
Check the CMS Coverage website for the current list of approved IDE studies before billing: cms.gov/Medicare/Coverage/IDE/Approved-IDE-Studies.html. This is the authoritative source. Your medical directors and clinical trial coordinators should have this URL bookmarked.
Category A Devices: What Medicare Advantage Will and Won't Pay
A Category A device is experimental in the truest sense — the FDA has not yet established whether the device type is safe and effective. CMS excludes Category A devices from coverage by statute. That exclusion is absolute. No prior authorization, no exception.
What UnitedHealthcare Medicare Advantage plans will pay for in a CMS-approved Category A IDE study is the routine care items and services — the visits, labs, imaging, and other standard care the member would receive regardless of trial participation. The device itself is not covered, period. Your charge capture needs to reflect that split cleanly.
The Medicare Advantage Organization (MAO) pays for routine care in Category A studies only when the MAC with jurisdiction over the MA plan's service area covers those routine care items. This is a layered coverage policy: CMS approval at the study level, MAC coverage at the service level. Both conditions must be met.
Category B Devices: Broader Coverage, Same CMS-Approval Requirement
A Category B device has cleared a higher bar. Initial questions of safety and effectiveness for that device type have been resolved — either through other manufacturers' FDA premarket approvals or clearance. What's still under study is the incremental risk of this specific device.
For CMS-approved Category B IDE studies, UnitedHealthcare Medicare Advantage plans cover both the device itself and the routine care items and services. This is a meaningfully different reimbursement picture than Category A.
The same MAC-jurisdiction requirement applies. The MAO pays for claims related to member participation in Category B studies that the MAC covers for the plan's service area.
Medicare-Approved Clinical Trials
Routine costs in Medicare-approved clinical trials are Medicare's financial responsibility — not the MA plan's, and not the member's. This matters for how your team submits claims and who you bill first. If you're billing a UnitedHealthcare MA plan for routine clinical trial costs that belong to Medicare, you're creating a payment responsibility mismatch that will generate denials.
UnitedHealthcare Experimental and Investigational Policy Exclusions and Non-Covered Indications
This coverage policy excludes all procedures, items, and medications that UnitedHealthcare classifies as experimental or investigational — across all specialties, all settings.
Category A devices are specifically and statutorily excluded from coverage. CMS cannot approve them for coverage even when approving the associated IDE study. Your reimbursement for a Category A study is limited to routine care only.
Any IDE study that has not received CMS centralized approval is not coverable under this policy. Claims submitted for non-CMS-approved studies will face claim denial without an effective path to appeal on coverage grounds — the study simply doesn't qualify.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Experimental or investigational procedures, items, medications | Not Covered | None listed | Classified as not Reasonable and Necessary |
| Category A device (experimental) — the device itself | Not Covered | None listed | Statutorily excluded; CMS cannot approve coverage |
| Routine care in CMS-approved Category A IDE study | Covered (MAO pays) | None listed | MAO pays; MAC jurisdiction must cover the services |
| Category B device — the device itself | Covered (MAO pays) | None listed | Requires CMS-approved Category B IDE study |
| Routine care in CMS-approved Category B IDE study | Covered (MAO pays) | None listed | MAO pays; MAC jurisdiction must cover the services |
| Routine costs in Medicare-approved clinical trials | Covered (Medicare pays) | None listed | Medicare — not MAO — is the responsible payer |
UnitedHealthcare Experimental and Investigational Billing Guidelines and Action Items 2025
This is where most billing teams lose money on IDE and clinical trial claims — not from getting the clinical classification wrong, but from misrouting the claim or missing a step in the approval chain.
| # | Action Item |
|---|---|
| 1 | Verify CMS approval status for every IDE study before September 26, 2025. Pull the CMS-approved IDE study list from cms.gov/Medicare/Coverage/IDE/Approved-IDE-Studies.html. For any study currently generating claims on your UnitedHealthcare MA patients, confirm it appears on that list. If it doesn't, stop billing those claims and contact your compliance officer before the effective date. |
| 2 | Classify every IDE study claim as Category A or Category B before billing. Category A and Category B trigger different coverage rules and different payer responsibilities. Tag this in your billing system so your team isn't making this determination claim by claim at submission. |
| 3 | Split your claim lines for Category A study patients. Routine care items and services are billable to the MAO. The Category A device is not. If your charge capture bundles device costs with routine care, separate them now. Bundled claims will either deny or generate overpayments that become repayment demands. |
| 4 | Confirm MAC jurisdiction coverage for routine care before billing the MAO. The MAO only pays routine care when the MAC with jurisdiction over the plan's service area covers those services. If you haven't mapped your UnitedHealthcare MA plans to their corresponding MAC jurisdictions, do that before billing IDE study claims. Your UHC provider relations contact can confirm the applicable MAC. |
| 5 | Route clinical trial routine costs to Medicare, not to UnitedHealthcare. For Medicare-approved clinical trials, Medicare is the financially responsible payer for routine costs. Billing these to the MA plan is a billing error — even if the patient is enrolled in a UnitedHealthcare MA plan. Review your clinical trial billing workflows to make sure this routing is clean. |
| 6 | Review your prior authorization process for any IDE-related services. This policy doesn't detail specific prior authorization requirements for IDE study routine care, but your UHC MA contracts may include prior auth requirements for services delivered in a trial setting. Check your contract terms and talk to your compliance officer if you're unsure how prior auth applies to your trial population. |
| 7 | Update your ABN process for experimental item requests. When a member requests a service your team knows is experimental or investigational — and therefore not covered — issue an Advance Beneficiary Notice before rendering the service. This protects you from liability and sets member expectations correctly. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Experimental and Investigational Procedures Under UHC Policy
This coverage policy does not list specific CPT, HCPCS, or ICD-10 codes. The policy is structural — it defines the payment responsibility framework for IDE studies and clinical trials rather than identifying specific procedure codes as covered or excluded.
Your team should not expect a code-level lookup to resolve coverage questions under this policy. Coverage determination depends on:
- Whether the IDE study has CMS centralized approval
- Whether the device is Category A or Category B
- Whether the MAC with jurisdiction over the plan's service area covers the routine care services
- Whether the trial qualifies as a Medicare-approved clinical trial for purposes of routine cost coverage
For any specific services delivered in an IDE study or clinical trial context, cross-reference the applicable Medicare Benefit Policy Manual (Chapter 14, §20), Medicare Claims Processing Manual (Chapter 32, §68), and Medicare Managed Care Manual (Chapter 4, §10.7.2) to determine how individual procedure codes interact with this framework.
If you're billing for complex trial protocols across multiple UnitedHealthcare Medicare Advantage plans and aren't certain how these rules apply to your specific service mix, loop in your compliance officer and billing consultant before September 26, 2025.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.